Dr. Crotty received his B.S. in Biology from the Massachusetts Institute of Technology (MIT) in 1996. He also received a B.S. in Writing from MIT the same year. Dr. Crotty undertook graduate work in virology at the University of California, San Francisco in the Program in Biological Sciences. There he discovered the mechanism of action of the antiviral drug ribavirin, widely used to treat chronic hepatitis C infections. Dr. Crotty earned his Ph.D. in Biochemistry and Molecular Biology in 2001. He then pursued postdoctoral work at the Emory University Vaccine Center with Dr. Rafi Ahmed from 2001 to 2003, studying aspects of the generation and maintenance of immune memory after viral infections. In 2003, he accepted a faculty position at LJI.

The Crotty lab has helped established that follicular helper T cells (Tfh) are a distinct type of differentiated CD4 T cell uniquely specialized in B cell help, and that Tfh differentiation is controlled by the transcription factor Bcl6 (Science 2009). He has made major advances in the area of T cell help to B cells, and through this work has become an internationally recognized leader in the field of Tfh cell biology (Annual Review of Immunology 2011). Dr. Crotty was named a Pew Scholar in Biomedical Sciences in 2005, and was the recipient of the annualAmerican Association of Immunologists (AAI) Investigator Award for outstanding early-career research contributions to the field of Immunology in 2012.

Dr. Crotty is also the author of Ahead of the Curve, a biography of Nobel laureate scientist David Baltimore, published in 2001, and reviewed in The Wall Street Journal, Nature, The Washington Post, The Journal of the American Medical Association (JAMA), Nature Medicine, and Discover Magazine.

Powerful HIV-neutralizing response possible in most people, study by San Diego researchers finds

Understanding what takes place will help researchers determine how well new HIV vaccines are guiding the immune response, said vaccine researcher Shane Crotty of the La Jolla Institute for Allergy & Immunology, a lead author of the study.

LJI scientist Shane Crotty makes the list of “Highly Cited Researchers” – again

“Vaccine development still relies primarily on trial and error and vaccine candidates either work or fail,” says Dr. Crotty. “That’s a really inefficient way of making progress. What we really want is to turn it into an engineering problem.”

No Research/Citations

T cells take the lead in controlling SARS-CoV-2 and reducing COVID-19 disease severity

A multi-layered, virus-specific immune response is important for controlling SARS-CoV-2 during the acute phase of the infection and reducing COVID-19 disease severity, with the bulk of the evidence pointing to a much bigger role for T cells than antibodies.
16-Sep-2020 02:55:57 PM EDT

LJI scientists receive $3.5 million to investigate role of immune cells in Parkinson's disease

Scientists at the La Jolla Institute for Immunology (LJI) have received $3.5 million as part of a team award from Aligning Science Across Parkinson’s (ASAP) to support a three-year study into how immune cells may contribute to Parkinson's disease.
15-Sep-2020 01:45:14 PM EDT

Beating HIV and COVID-19 may depend on tweaking vaccine molecules

In a new Immunity study, researchers at La Jolla Institute for Immunology (LJI) show that one way to improve the body's immune response to vaccines is to factor in antigen valency. Valency refers to the number of antibody binding sites on an antigen.
27-Aug-2020 03:45:55 PM EDT

LJI Scientists Investigate a Powerful Protein Behind Antibody Development

Scientists at the La Jolla Institute for Immunology (LJI) have discovered a potential new way to better fight a range of infectious diseases, cancers and even autoimmune diseases. The new study, published recently in Nature Immunology, shows how a protein works as a “master regulator” in the immune system.
17-Jun-2020 04:35:41 PM EDT

First detailed analysis of immune response to SARS-CoV-2 bodes well for COVID-19 vaccine development

A study by researchers at La Jolla Institute for Immunology documents a robust antiviral immune response to SARS-CoV-2 in a group of 20 adults who had recovered from COVID-19. The findings show that the body’s immune system is able to recognize SARS-CoV-2 in many ways, dispelling fears that the virus may elude ongoing efforts to create an effective vaccine.
14-May-2020 06:05:47 PM EDT

"Infectious diseases kill more people worldwide than any other single cause. That’s one of the main reasons I focus on vaccines. They really have the potential for improving lives and saving lives."

Media mobile No : 8583577481

Media office Phone : 8587526640

Media email : gina@lji.org

No Video